We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
- Authors
Tembhare, Prashant R; Marti, Gerald; Wiestner, Adrian; Degheidy, Heba; Farooqui, Mohammed; Kreitman, Robert J; Jasper, Gregory A; Yuan, Constance M; Liewehr, David; Venzon, David; Stetler-Stevenson, Maryalice
- Abstract
Anti-CD20 (rituximab), anti-CD52 (alemtuzumab), anti-CD22 (BL22, HA22), and anti-CD25 (Oncotac) are therapeutic options that are the mainstay or in preclinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to monoclonal antibody-based therapy.
- Publication
American journal of clinical pathology, 2013, Vol 140, Issue 6, p813
- ISSN
1943-7722
- Publication type
Journal Article
- DOI
10.1309/AJCPYFQ4XMGJD6TI